OncoMed Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 10 of 10 Posts
Premarket Biotech Digest – CBMG Inks New Deal, IPCI Sued, SYRS Gets FDA Nod
Article By: KKD Healthcare Analytics Tuesday, April 11, 2017 9:34 AM EDT
Geron Corporation stock picked up on the news that the company has agreed to a settlement related to a consolidated class-action securities lawsuit. The company stock jumped over 19 percent in its previous trading session.
In this article: TXMD, GERN, IPCI, RPRX, GBLX, OMED, CBMG, SYRS
Read
OncoMed Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Wednesday, August 17, 2016 11:15 PM EDT
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock.
In this article: OMED
Read
4 Post-Sell-Off Bargain Stocks In Biotech
Article By: Bret Jensen Tuesday, August 25, 2015 10:02 PM EDT
The biotech sector, after a miraculous run that saw the main indices shoot up more than 50% in a year until this recent pullback, has given up 15% from its recent peak.
In this article: CLVS, ZIOP, MACK, OMED Also: GSK, AMGN, CELG, GILD
Read
A Good Run Continues
Article By: Gary Tanashian Tuesday, April 14, 2015 9:00 PM EDT
I believe now is a good time for swing trading. Swing trading is defined here as the act of taking positions on downside buying opportunities and holding through some ups and down and then forcing myself to take profits when they are presented.
In this article: INTC, DEPO, BCLI, OMED, VCEL
Read
Biotech Updated - April 7, 2015
Article By: Gary Tanashian Tuesday, April 7, 2015 12:20 PM EDT
A trend is not over until the trend is over. Lately there have been many posts, research and articles discussing the end of the Biotech rally. Okay fine, but the charts at least, have not indicated that yet.
In this article: IBB, BTK, SOX, OMED
Read
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Article By: BioMedReports Friday, January 16, 2015 3:44 AM EDT
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI
Read
Silly Season?
Article By: Gary Tanashian Friday, January 2, 2015 7:54 PM EDT
Several items I have been holding, trading and noting as seasonal plays are getting peppy: a look at mostly risky stocks I hold as speculations.
In this article: OMED, SIMO, DARA, SGI, CTRL
Read
OMED Offers Data From Demcizumab; CELG Receives Positive CHMP Opinion For OTEZLA
Article By: BioMedReports Monday, November 24, 2014 3:23 AM EDT
OMED a clinical-stage company presenting data in two posters, highlighting the company's translational research and biomarker efforts for its tarextumab. CELG announced that the (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA.
In this article: CELG, OMED
Read
OncoMed (OMED); Lottery Ticket Cashed
Article By: Gary Tanashian Monday, June 9, 2014 11:31 AM EDT
OncoMed has been noted in NFTRH as a “lottery ticket” hold over the last several week and today I am taking the 14% off the little bottoming pattern, which by the way, measures to 26+.
In this article: OMED
Read
OncoMed Pharmaceuticals (OMED) Still On Radar
Article By: Gary Tanashian Monday, March 31, 2014 1:54 PM EDT
Since I considered the news that originally launched OMED to be fundamentally sound as opposed to hype, I’ve kept it on radar all these months. On Friday I saw it sitting at support and decided to take a shot.
In this article: OMED
Read
1 to 10 of 10 Posts